BioRxiv

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights

Retrieved on: 
tisdag, maj 14, 2024
PROMIS, Patient, CSF, Pharmacokinetics, SOD1, Toxicity, Immunoglobulin G, Synucleinopathy, Trial of the century, Safety, ALS, Biochemistry, Blood, PMN, Bioorganic chemistry, Vaccination, BioRxiv, Cerebrospinal fluid, Journal, Multiple system atrophy, Research, Therapy, MSA, Biotechnology, Epitope, Neuroscience, Pharmaceutical industry

In January 2024, ProMIS announced the selection of a lead vaccine candidate, PMN400, against multiple synucleinopathies including MSA, Parkinson’s disease and Lewy Body Dementia.

Key Points: 
  • In January 2024, ProMIS announced the selection of a lead vaccine candidate, PMN400, against multiple synucleinopathies including MSA, Parkinson’s disease and Lewy Body Dementia.
  • In January 2024, ProMIS announced the appointment of Neil Warma as the interim Chief Executive Officer.
  • General and administrative expenses modestly increased to $1.6 million for the quarter ended March 31, 2024, compared to $1.4 million for the same period in 2023.
  • Net loss was $3.6 million for the quarter ended March 31, 2024, compared to a net loss of $5.0 million for the same period in 2023.

Sangamo Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results

Retrieved on: 
torsdag, maj 9, 2024
Biotechnology, Neurology, Health, Genetics, Pharmaceutical, STAC, FDA, CTA, Haemophilia, Enzyme replacement therapy, Kite, Investment, Nav1.7, Fabry disease, Poster, Disease, ERT, Sigma-Aldrich, STAAR, Health care, MAA, Partnership, Sangamo Therapeutics, MINT, AAV, Ligand Pharmaceuticals, IND, Tauopathy, Novartis, DNA, Patient, Pivotal, DSM-IV codes, EMA, Prion, BBB, Genome, BLA, MHRA, Manuscript, BioRxiv, Capsid, Modularity, Biogen, Therapy, Food and Drug Administration, European Medicines Agency, Gene, Pharmaceutical industry

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported business highlights and first quarter 2024 financial results.
  • “We are pleased with the progress being made in business development discussions across our portfolio, including our Fabry disease program.
  • An IND submission is expected in the fourth quarter of 2024.
  • Revenues for the first quarter ended March 31, 2024 were $0.5 million, compared to $158.0 million for the same period in 2023.

New Discovery Identifies “Don’t Eat Me” Protein that Allows Lyme Bacteria to Evade Body’s Immune Response

Retrieved on: 
tisdag, maj 7, 2024
SIRP, Stanford University, Massachusetts Institute of Technology, University, Cancer, CD47, Hope, Infection, Regenerative medicine, CD24, Bacteria, MD, Doctor of Philosophy, Research, Borrelia burgdorferi, Therapy, Atherosclerosis, Lyme disease, Patient, Macrophage, PALO, Diagnosis, BioRxiv, BAL, Immune system, P66, Escape Room, Vaccine

The research was conducted at Stanford University and University of California San Francisco and funded in part by Bay Area Lyme Foundation.

Key Points: 
  • The research was conducted at Stanford University and University of California San Francisco and funded in part by Bay Area Lyme Foundation.
  • This groundbreaking data posted on bioRxiv on April 30, 2024, is expected to be published in a peer-review journal in the future.
  • “One of the big mysteries of Lyme disease has been how Borrelia is able to evade and survive the immune system – and this study helps answer that question.
  • “Patients need both a robust immune response and antibiotics to eradicate an infection - antibiotics alone are not usually sufficient.

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing

Retrieved on: 
torsdag, maj 9, 2024
Biotechnology, Health, Genetics, Pharmaceutical, Health Technology, Risk, Poster, Disease, LNP, Cell, Sangamo Therapeutics, MINT, Publication, AAV, DNA, Patient, Gene, Society, Genome, Manuscript, BioRxiv, Modularity, Annual general meeting, Therapy, Vaccine

Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.

Key Points: 
  • Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today presented pre-clinical data showcasing its novel next-generation integrase technology engineered to enable large-scale genome editing.
  • Building on Sangamo’s deep expertise in protein-DNA interactions derived from its zinc finger platform, the Modular Integrase (MINT) platform is a versatile, protein-guided genome editing method designed to integrate large sequences of DNA into the genome to potentially treat – with a single medicine – patients who have unique mutations in the same gene.
  • “Precisely integrating large DNA constructs into desirable chromosomal sites has traditionally been challenging for the field.
  • We are excited that our new MINT platform potentially addresses this long-standing problem and would allow us to pursue new indications by inserting or replacing entire genes,” said Greg Davis, Ph.D., Head of Technology at Sangamo.

Sampling Human Ships its First Kits for Cellular Analysis to Early Access Customers and Releases an App Note with BMG LABTECH

Retrieved on: 
måndag, maj 6, 2024
Research, Medical Devices, Genetics, Health Technology, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, BMG, Cell biology, Single-cell analysis, Luminescence, Apoptosis, Microplate, Organoid, Partnership, Sampling, University, Early access, CBEC, BioRxiv, Student, Drug discovery

Sampling Human, Inc. , a techbio company developing single cell technologies, announces the delivery of its Apoptosis (Anti-PS) Biocytometry Kits to Early Access customers.

Key Points: 
  • Sampling Human, Inc. , a techbio company developing single cell technologies, announces the delivery of its Apoptosis (Anti-PS) Biocytometry Kits to Early Access customers.
  • In addition, Sampling Human has partnered with BMG LABTECH to release an application note pairing their kits with BMG LABTECH microplate readers.
  • Daniel Georgiev, co-founder and chief executive officer of Sampling Human, will be speaking on applications for the technology at the SynBioBeta conference.
  • “At Sampling Human, we recognize the great lengths scientists go to today in order to obtain high-quality single-cell data,” said Daniel Georgiev.

Modalis Therapeutics Reports Data Supporting Development of a Transformative Epigenome Editing Therapeutic, MDL-101: a First-in-Class Epigenome Editing approach for the Treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2-CMD)

Retrieved on: 
tisdag, maj 7, 2024
Health, Genetics, Research, Pharmaceutical, Science, Biotechnology, Dicarboxylic acid, Metadata, DSM-IV codes, CRISPR, DOI, Safety, LAMA1, LAMA2, AAV, Tokyo Stock Exchange, DNA, Therapy, Patient, Congenital muscular dystrophy, Gene expression, Manuscript, BioRxiv, Vaccine

The company reported data demonstrating exceptional durability, robust efficacy and safety in dyW mouse disease model of LAMA2-CMD and in adult and juvenile NHPs.

Key Points: 
  • The company reported data demonstrating exceptional durability, robust efficacy and safety in dyW mouse disease model of LAMA2-CMD and in adult and juvenile NHPs.
  • LAMA2-CMD is a severe, early onset congenital muscular dystrophy caused by the absence of the LAMA2 protein.
  • No approved therapies to address the root cause of this condition exist or are in clinical trials.
  • "We are thrilled to post our comprehensive preclinical data supporting the development of MDL-101 on bioRxiv.

Ring Therapeutics Publishes a Novel Gene Delivery Platform Based on the Commensal Human Anellovirus

Retrieved on: 
måndag, april 1, 2024
Cell, Patient, Mouse, Flagship Pioneering, MD, Tropism, Biology, MBA, Iris (anatomy), Publication, Therapy, RPE, Immune system, Immune privilege, BioRxiv, Vaccine

CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize programmable medicines with its commensal virome platform, today announced a pre-print publication in bioRxiv featuring the first gene delivery vector system based on a human commensal virus, the anellovirus. These data support the immense promise of Ring’s AnellogyTM platform, harnessing the unique biology of commensal anelloviruses to engineer the next generation of durable and potentially redosable programmable viral vectors.

Key Points: 
  • – Publication describes the first gene delivery vector system based on a human commensal virus, the anellovirus –
    CAMBRIDGE, Mass., April 01, 2024 (GLOBE NEWSWIRE) -- Ring Therapeutics, a life sciences company founded by Flagship Pioneering to revolutionize programmable medicines with its commensal virome platform, today announced a pre-print publication in bioRxiv featuring the first gene delivery vector system based on a human commensal virus, the anellovirus.
  • These data support the immense promise of Ring’s AnellogyTM platform, harnessing the unique biology of commensal anelloviruses to engineer the next generation of durable and potentially redosable programmable viral vectors.
  • “We set out to develop an entirely new vector system based on human commensal viruses to address the many hurdles facing current genetic medicine delivery – and we’ve achieved that goal at remarkable speed,” said Tuyen Ong, MD, MBA, Chief Executive Officer of Ring and CEO-Partner at Flagship Pioneering.
  • This technology could enable the Anellogy platform to take advantage of the remarkable diversity of anelloviruses.

Model Medicines Unveils Groundbreaking AI Drug Discovery Advances in New Chemistry and New Biology with Two New Preprint Papers

Retrieved on: 
tisdag, april 9, 2024
AXL, Infection, Drug discovery, COVID-19, RNA-dependent RNA polymerase, FACP, FIDSA, RNA, Research, Publishing, AI, UC San Diego Health, Deep learning, GALILEO, Preprint, Orthornavirae, Therapy, Pandemic, BioRxiv, MAS, BRD4

LA JOLLA, Calif., April 9, 2024 /PRNewswire/ -- Model Medicines, a leading human health company specializing in generative AI-driven drug discovery, today announced the publication of two significant preprint papers on bioRxiv detailing major advances in antiviral and oncology drug discovery.

Key Points: 
  • LA JOLLA, Calif., April 9, 2024 /PRNewswire/ -- Model Medicines, a leading human health company specializing in generative AI-driven drug discovery, today announced the publication of two significant preprint papers on bioRxiv detailing major advances in antiviral and oncology drug discovery.
  • Using bioinformatics and deep learning, they also found MDL-001 to be a promising orally bioavailable broad-spectrum antiviral that blocks the RdRp Thumb-1 site.
  • In the second preprint, "ChemPrint: An AI-Driven Framework for Enhanced Drug Discovery" , Model Medicines details their foundational GALILEO AI platform and its core ChemPrint deep learning model for molecular property prediction.
  • By employing adaptive molecular embeddings and rigorous model training and validation methods, ChemPrint substantially outperformed conventional AI approaches.

Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
tisdag, mars 19, 2024
Atopic dermatitis, Head, T helper cell, HNSCC, Patient, PTCL, Lung cancer, Ipilimumab, Asthma, CTCL, ALCL, Fungal infection, Pulmonary fibrosis, Lymphocyte, RCC, Clinical trial, CRS, Marketing, B-cell lymphoma, Research, PR, PTCL-NOS, Psoriasis, T-cell lymphoma, ASH, Webcast, Immunomodulation, Pembrolizumab, PRS, Exposition, Cancer, Nivolumab, Safety, Scleroderma, Food, NSCLC, Teva Pharmaceuticals, Modified, Lymphoma, Knowledge, Allergy, Immunodeficiency, Time management, Peripheral, Poster, FDA, ITK, Conference call, Kidney cancer, T helper 17 cell, Society, Preprint, BioRxiv, Autoimmunity, Physician, Total, Pharmaceutical industry

BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • ET / 1:30 p.m. PT
    BURLINGAME, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (Corvus or the Company) (Nasdaq: CRVS) (GLOBAL NEWSWIRE), a clinical-stage biopharmaceutical company, today provided a business update and reported financial results for the fourth quarter and year ended December 31, 2023.
  • We have several exciting opportunities in immunology, including plans for a randomized, placebo controlled clinical trial of soquelitinib in atopic dermatitis.
  • Mr. Arcara previously served as senior vice president, head global marketing & portfolio and strategy for the innovative medicines and biosimilars business at Teva Pharmaceuticals.
  • ET (1:30 p.m. PT), during which time management will provide a business update and discuss the fourth quarter and full year 2023 financial results.

AB Science: New research shows that masitinib limits neuronal damage in a model of neuroimmune-driven neurodegenerative disease

Retrieved on: 
onsdag, mars 13, 2024
Neurology, Serum, EAE, Multiple sclerosis, ALS, Disease, Patient, Biomarker, Masitinib, Research, Mouse, Science, University, MD, Euronext, Alzheimer's disease, Cytokine, AN, BioRxiv, FDA, NFL, Nerve, FIRST, AFL, NDD, Guideline, Pharmaceutical industry

Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.

Key Points: 
  • Findings have been published on the bioRxiv preprint service as an article entitled, ‘Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease’.
  • The neuroprotective action of masitinib was studied in an animal model of experimental autoimmune encephalitis (EAE).
  • Results showed that masitinib can significantly lower serum NfL levels, and by extension therefore, neuronal damage, in a neuroimmune-driven neurodegenerative disease model, with concomitant reduction in pro-inflammatory cytokines and slowing of clinical symptoms.
  • Masitinib limits neuronal damage, as measured by serum neurofilament light chain concentration, in a model of neuroimmune-driven neurodegenerative disease.